BSE: NGLFINECHEM CMP: Rs 3113.45 P/E: 46.44x ROCE: 15.07% 6M Ret: +119.27% Div Yld: 0.06% ATH: Rs 3789.45
Key Performance Indicators
NGL Fine Chem trades at Rs 3113.45 on BSE (NGLFINECHEM), with a market capitalisation of Rs 1933.20 crore. The price-to-earnings ratio is 46.44x. Return on capital employed stands at 15.07%. The six-month return is +119.27%. Quarterly net profit is Rs 11.35 crore (+2282.69% year-on-year change). Quarterly sales stand at Rs 144.75 crore (+55.61% year-on-year). The dividend yield is 0.06%. The all-time high is Rs 3789.45, 21.7% above the current price.
Highlights
NGL Fine Chem has delivered a six-month return of 119.27%, with a market capitalisation of Rs 1933.20 crore at the current price of Rs 3113.45. The all-time high of Rs 3789.45 sits 21.7% above the current price, indicating the stock has corrected from its historical peak and offers headroom for appreciation toward that level. The company's ROCE of 15.07% — above the 15% quality threshold, indicating the business generates meaningful returns above the cost of capital — is a key distinguishing fundamental metric.
The P/E of 46.44x carries a moderate growth premium relative to the Indian market average, pricing in above-economy earnings growth expectations. The dividend yield of 0.06% provides a meaningful income component — a signal of cash generation capability and management's willingness to return capital. The industrials sector tailwinds — industrial PLI schemes, infrastructure investment, and manufacturing growth — provide structural support for sustained revenue and earnings growth.
Business Overview
NGL Fine Chemicals manufactures veterinary active pharmaceutical ingredients (APIs) and pharmaceutical intermediates, serving animal health companies globally with high-purity APIs for antiparasitic, antibiotic, and veterinary therapeutic products. The veterinary API segment is a specialised, higher-margin niche within the broader Indian pharmaceutical API market — requiring regulatory compliance with multiple drug control agencies and supplying to branded animal health companies that demand consistent quality and supply security.
The quarterly profit growth of 2,282.69% — from a near-zero prior year base to Rs 11.35 crore — on revenue of Rs 144.75 crore growing 55.61% reflects a dramatic business acceleration. While the percentage growth is mathematically amplified by the low starting base, the absolute profit and revenue scale are meaningful. The ROCE of 15.07% crosses the 15% quality threshold. The P/E of 46.44 times is reasonable for a veterinary API specialist with demonstrated growth. The six-month return of 119.27% and the all-time high of Rs 3,789.45 — Rs 675 above the current price of Rs 3,113.45 — indicate significant headroom to the historical peak.
Financial Analysis
NGL Fine Chem's most recent quarterly financial results show revenue of Rs 144.75 crore (+55.61% year-on-year) and net profit of Rs 11.35 crore (2282.69% year-on-year variation). The triple-digit profit growth rate substantially outpaces revenue growth — a pattern that signals meaningful margin expansion, operating leverage taking effect, or non-recurring income contribution that should be verified through the quarterly results commentary.
The ROCE of 15.07% is the primary quality indicator for this business. At 15.07%, the business crosses the threshold that Warren Buffett famously cited as a hallmark of exceptional businesses — generating returns on capital substantially above typical cost of capital levels, creating economic value with each rupee reinvested.
At Rs 1933.20 crore — a small-cap company — NGL Fine Chem may have limited institutional research coverage, making self-directed analysis of BSE exchange filings, quarterly results, and annual reports especially important for investors forming an investment view.
Investor Highlights
The investment case for NGL Fine Chem rests on the combination of a 15.07% ROCE — indicating a capital-efficient business with sustainable competitive advantages — and a demonstrated revenue and earnings growth trajectory that supports the current P/E of 46.44x. The combination of solid ROCE with consistent earnings growth creates a compounding engine where both business scale and per-share earnings grow simultaneously, supporting share price appreciation over a full investment cycle.
With the current price 21.7% below the all-time high of Rs 3789.45, there is established headroom toward the historical peak. If fundamental performance continues to deliver quarterly profit growth and improving ROCE, the stock has a reference target for re-rating toward the all-time high level.
The dividend yield of 0.06% provides a foundational income return that is independent of capital appreciation — a meaningful characteristic for investors who value income alongside growth. A dividend-paying company with a positive ROCE above 15% is distributing cash it does not need for reinvestment at attractive rates, implying the business generates more cash than its optimal reinvestment requirements. Investors should access the company's latest annual report and quarterly results on the BSE/NSE portal for current financial data and management commentary on the growth outlook.
Frequently Asked Questions
Q: What does NGL Fine Chem do and why has it delivered a 119.27% six-month return?
A: NGL Fine Chem operates in India's industrials sector. The 119.27% six-month return reflects a combination of sector-level tailwinds, improving quarterly financial performance — quarterly profit growing 2282.69% and revenue growing 55.61% year-on-year — and market re-rating of the company's growth and quality profile. Specific business details and catalysts are documented in BSE/NSE exchange filings.
Q: What does the ROCE of 15.07% indicate about NGL Fine Chem's business quality?
A: NGL Fine Chem's ROCE of 15.07% measures pre-tax profit generated per rupee of total capital employed. At 15.07%, the business consistently generates returns above the typical cost of capital for Indian companies — a hallmark of businesses with durable competitive advantages, whether from technology, relationships, scale, or regulatory positioning. Tracking ROCE over multiple quarters provides a leading indicator of business quality improvement or deterioration.
Q: How does the P/E of 46.44x compare to fundamentals for NGL Fine Chem?
A: The P/E of 46.44x should be assessed in conjunction with the earnings growth rate and ROCE. At 46.44x, the stock carries a moderate premium relative to the market average of 20–25x, compensated in part by the ROCE of 15.07% and the quarterly earnings growth of 2282.69%.
Q: What is NGL Fine Chem's all-time high and how far is the current price from it?
A: NGL Fine Chem's all-time high is Rs 3789.45. The current price of Rs 3113.45 is 21.7% below the all-time high, offering potential headroom for appreciation if fundamental performance supports continued market re-rating. The all-time high provides a reference ceiling that informs sentiment and potential price target discussion, though fundamental value — determined by earnings, ROCE, and growth — is the primary determinant of sustainable price levels.
Q: Where can investors access NGL Fine Chem's official financial data and disclosures?
A: NGL Fine Chem's quarterly results, annual reports, investor presentations, shareholding patterns, and all material corporate announcements are filed with BSE and are freely accessible through the exchange filing portals at nseindia.com and bseindia.com. SEBI listing regulations mandate timely disclosure of all financial results and material developments. These filings are the primary source of verified financial and operational data for investment analysis.